- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05278299
Asia Glaucoma Registry
Přehled studie
Postavení
Podmínky
Detailní popis
Glaucoma remains a leading cause for irreversible visual impairment and blindness worldwide and it disproportionately affects people residing in Asia [Tham et al, 2014]. It is well established that the epidemiology and natural history of glaucoma in patients in the Asia region is different from its western counterparts. Compared with the other parts of the world, the prevalence of primary angle closure glaucoma (PACG) was highest in Asia [Tham et al, 2014]. The prevalence of PACG was higher in East Asia than South East Asia, while the burden of primary open angle glaucoma (POAG) was projected to be the highest in South-Central Asia by 2040 [Chan et al, 2016]; this suggests that ethnic differences within Asia may be a contributing factor to the differences in the prevalence of different types of glaucoma. Furthermore, studies have suggested the prevalence of normal pressure glaucoma is also higher in Asians than Caucasians [ Chen et al , 2020 ] Given the disproportionate burden of glaucoma in Asia, there is a need to ensure optimal management of the disease in patients with glaucoma. The ability to estimate the rates of structural and functional loss in patients with glaucoma will enable clinicians to identify those with rapidly deteriorating conditions or those at-risk, and to therefore provide timely treatment to these patients.
Despite this, there are currently several challenges in identifying rapid-progressors in glaucoma, including lack of consensus on the definition of 'rapid' progression and what rates of change of visual field (VF) encompass clinically significant deterioration relevant to the patients. As such, the Asia Glaucoma Registry is intended to collect data to advance the understanding of glaucoma and its progression in Asia and to understand the management patterns of glaucoma in Asia. The Registry will also provide research data for future collaborative scientific research projects. Glaucoma remains a leading cause for irreversible visual impairment and blindness worldwide and it disproportionately affects people residing in Asia [Tham et al, 2014]. It is well established that the epidemiology and natural history of glaucoma in patients in the Asia region is different from its western counterparts. Compared with the other parts of the world, the prevalence of primary angle closure glaucoma (PACG) was highest in Asia [Tham et al, 2014]. The prevalence of PACG was higher in East Asia than South East Asia, while the burden of primary open angle glaucoma (POAG) was projected to be the highest in South-Central Asia by 2040 [Chan et al, 2016]; this suggests that ethnic differences within Asia may be a contributing factor to the differences in the prevalence of different types of glaucoma. Furthermore, studies have suggested the prevalence of normal pressure glaucoma is also higher in Asians than Caucasians [ Chen et al , 2020 ] Given the disproportionate burden of glaucoma in Asia, there is a need to ensure optimal management of the disease in patients with glaucoma. The ability to estimate the rates of structural and functional loss in patients with glaucoma will enable clinicians to identify those with rapidly deteriorating conditions or those at-risk, and to therefore provide timely treatment to these patients.
Despite this, there are currently several challenges in identifying rapid-progressors in glaucoma, including lack of consensus on the definition of 'rapid' progression and what rates of change of visual field (VF) encompass clinically significant deterioration relevant to the patients. As such, the Asia Glaucoma Registry is intended to collect data to advance the understanding of glaucoma and its progression in Asia and to understand the management patterns of glaucoma in Asia. The Registry will also provide research data for future collaborative scientific research projects.
References:
Chan EW, et al. Glaucoma in Asia: regional prevalence variations and future projections. Br J Opthalmol 2016;100(1):78-85.
Chen MJ. Normal tension glaucoma in Asia : Epidemiology, pathogenesis, diagnosis, and management. Taiwan J Ophthalmo ;10 250-4. He M, et al. Angle-closure glaucoma in East Asian and European people. Different diseases? Eye (Lond) 2006;20(1):3-12.
Tham Y, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and metaanalysis. Ophthalmology 2014;121(11):2081-90.
Yip JLY, Foster PJ. Ethnic differences in primary angle-closure glaucoma. Curr Opin Ophthalmol 2006;17(2):175-80.
Typ studie
Zápis (Očekávaný)
Kontakty a umístění
Studijní místa
-
-
-
Hong Kong, Hongkong
- Leung Kai Shun
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Patients with a diagnosis of POAG or PACG
- Age ≥18 years at diagnosis.
- Have reliable VF tests obtained from Humphrey Field Analyzer (HFA) using the same testing strategy on average once a year over 6-7 years backward in at least one eye (the included eye must have evidence of glaucoma as defined above). A reliable VF test has fixation losses ≤20% and false positive errors ≤15%. All criteria mentioned above must be met for inclusion into the study. Both eyes will be included if both eyes meet the inclusion criteria.
Exclusion Criteria:
- Secondary causes of glaucoma (e.g. uveitic glaucoma, neovascular glaucoma, traumatic glaucoma, exfoliative glaucoma, pigmentary glaucoma, phacomorphic glaucoma, malignant glaucoma)
- Any neurological disease that may result in VF loss (e.g. stroke)
- History of optic neuropathy other than glaucoma (including those related to thyroid eye disease);
- Prior retinal surgery.
Studijní plán
Jak je studie koncipována?
Detaily designu
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
The proportion of fast progressors among patients with POAG or PACG and the risk factors for fast progression
Časové okno: 1 year
|
1 year
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
The severity and spectrum of glaucoma in different ethnic groups in Asia and the practice patterns of glaucoma management in Asia
Časové okno: 1 year
|
1 year
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Kai Shun, Christopher Leung, The University of Hong Kong
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- UW 21-664
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na POAG
-
BelkinVisionSingapore Eye Research InstituteZatím nenabíráme
-
Oertli Instrumente AGUniversity of Geneva, SwitzerlandNeznámýGlaukom | Šedý zákal | POAGNěmecko, Švýcarsko, Egypt, Indie
-
New World Medical, Inc.Zatím nenabírámePOAGKostarika, Honduras, Mexiko
-
Centre Hospitalier Universitaire, AmiensCentral Hospital Saint QuentinNábor
-
Transcend Medical, Inc.DokončenoPrimární glaukom s otevřeným úhlem (POAG)
-
Glaukos CorporationDokončenoPrimární glaukom s otevřeným úhlem (POAG)Arménie
-
Glaukos CorporationDokončenoSubjekty s primárním glaukomem s otevřeným úhlem (POAG)Arménie
-
Implandata Ophthalmic Products GmbHDokončenoPrimární glaukom s otevřeným úhlem (POAG)Německo
-
Glaukos CorporationUkončenoPrimární glaukom s otevřeným úhlem (POAG)Brazílie
-
Glaukos CorporationDokončenoPrimární glaukom s otevřeným úhlem (POAG)Arménie